Market Size of Global Cholera Vaccines Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 9.80 % |
Fastest Growing Market | North America |
Largest Market | Asia Pacific |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Cholera Vaccines Market Analysis
The cholera vaccines market is poised to grow at a CAGR of 9.8% over the forecast period.
The COVID-19 pandemic impacted the growth of the cholera vaccine market. For instance, an article published by the International Journal of Public Health in June 2021, reported cholera case fatality rate (CFR) increased in 2020 in Central and West Africa. CFR rose from 1.8% in 2019 to 2.1% in 2020. The COVID-19 pandemic has decreased health promotion activities that mitigate cholera outbreaks, and thus cases of cholera cases significantly increased. Thus, the increasing number of cholera cases reported during the COVID-19 pandemic increased the demand for cholera vaccines. In the current scenario, due to the decrease in COVID-19 cases and the resumption of healthcare services, the treatment of cholera is easily available, and the demand for the cholera vaccine may get stabilized compared to the beginning of the pandemic. In addition, with the rising number of cholera cases, the market is expected to witness significant growth over the forecast period.
The factors that are driving the growth of the studied market are increasing incidences of cholera and rising initiatives and awareness regarding immunization. For instance, in December 2022 World Health Organization (WHO) reported that since 2021, there had been an increase in cholera cases and their geographical distribution globally. The source also repeated that in the year 2021, 23 countries reported cholera outbreaks, mainly in the WHO Regions of Africa and the Eastern Mediterranean.
Similarly, an article published by the journal The Lancet Regional Health South Asia in July 2022 reported 6,231 suspected cholera cases were recorded in Pakistan and Bangladesh from January 2022 to April 2022. Thus, the high number of cholera cases recorded globally is expected to increase the demand for cholera vaccines, thereby driving the growth of the studied market.
Also, the increasing research and developments in Asia are expected to drive the growth of the market. For instance, in October 2021, CSIR- Indian Institute of Chemical Biology developed an oral cholera vaccine with an avirulent culture of an El Tor vibrio strain isolated from a water source in India and had successful testing on human volunteers. Thus, such studies are leading to the development of new vaccines, thereby driving the growth of the studied market.
Furthermore, the increased funding for the development of cholera vaccines by various organizations is expected to drive the growth of the market. For instance, in January 2022, The International Vaccine Institute (IVI) received a USD 1.4 million grant from the Bill and Melinda Gates Foundation to ensure critical standards and reagents. These funds are available to the manufacturers that produce cholera vaccines at a lower price in the global health market.
Thus, the increasing incidences of cholera and rising initiatives and awareness regarding immunization are expected to drive the demand for cholera vaccines, thereby contributing to the growth of the market during the forecast period. However, a lack of access to adequate care for cholera, coupled with many unreported cases, is expected to pull back the growth of the market.
Cholera Vaccines Industry Segmentation
As per the scope of the report, cholera is caused by Vibrio cholerae via the consumption of contaminated food or water. The infected individuals suffer from severe watery diarrhea, eventually leading to dehydration, which, if unattended, may lead to death owing to access water loss. Oral vaccination has been observed to be the best preventive treatment for cholera and has proved to be very useful in preventing huge outbreaks.
The Cholera Vaccines Market is segmented by Vaccine Type (Whole cell V. cholerae O1 with Recombinant B-subunit, Killed Oral O1, and O139), Product (Vaxchora, Dukoral, Shanchol, and Other Products), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
By Vaccine Type | |
Whole cell V. cholerae O1 with Recombinant B-subunit | |
Killed Oral O1 and O139 |
By Product | |
Vaxchora | |
Dukoral | |
Shanchol | |
Other Products |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Cholera Vaccines Market Size Summary
The cholera vaccines market is experiencing robust growth, driven by an increase in cholera cases globally and heightened awareness and initiatives surrounding immunization. The COVID-19 pandemic initially hindered market expansion by reducing health promotion activities, leading to a rise in cholera cases, particularly in Central and West Africa. However, as healthcare services resume and COVID-19 cases decline, the demand for cholera vaccines is expected to stabilize. The market's growth is further supported by ongoing research and development efforts, particularly in Asia, where new vaccine formulations are being tested. Increased funding from organizations like the Bill and Melinda Gates Foundation is also facilitating the production of cholera vaccines at lower costs, contributing to market expansion.
Regionally, North America is anticipated to witness significant growth due to advanced research and the presence of major pharmaceutical players. The high incidence of cholera cases in Mexico and rising government initiatives to control the disease are key factors driving market growth in this region. The competitive landscape of the cholera vaccine market is highly fragmented, with numerous global and regional companies, including Astellas Pharma Inc., Emergent BioSolutions Inc., and GlaxoSmithKline plc, holding significant market shares. Collaborative efforts, such as Canada's financial contribution to increase vaccine production in Latin America and the Caribbean, further underscore the market's dynamic nature and potential for continued expansion.
Global Cholera Vaccines Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidences of Cholera
-
1.2.2 Rising Initiatives and Awareness Regarding Immunization
-
-
1.3 Market Restraints
-
1.3.1 Lack of Access to Adequate Treatment
-
-
1.4 Porter Five Forces
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Vaccine Type
-
2.1.1 Whole cell V. cholerae O1 with Recombinant B-subunit
-
2.1.2 Killed Oral O1 and O139
-
-
2.2 By Product
-
2.2.1 Vaxchora
-
2.2.2 Dukoral
-
2.2.3 Shanchol
-
2.2.4 Other Products
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Cholera Vaccines Market Size FAQs
What is the current Global Cholera Vaccines Market size?
The Global Cholera Vaccines Market is projected to register a CAGR of 9.80% during the forecast period (2024-2029)
Who are the key players in Global Cholera Vaccines Market?
Sanofi, GlaxoSmithKline LLC, Astellas Pharma Inc, Pfizer Inc. and Merck & Co. Inc. are the major companies operating in the Global Cholera Vaccines Market.